Physician profile
Jay Klarnet
NPI 1538258314
$8,103.80
in general payments reported to CMS, 2019-2025
53 companies · $1,075 in 2025
The $1,075 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $749 · 2021: $1,341 · 2022: $1,306 · 2023: $1,753 · 2024: $1,264 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,815 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,815.41 |
| Education | $276.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $551.45 | 2022-2025 | Imfinzi, Lynparza |
| Beigene, LTD. | $525.00 | 2021 | |
| Incyte Corporation | $517.72 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $491.76 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $411.83 | 2019-2025 | |
| Sobi, INC | $375.97 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $366.74 | 2019-2025 | |
| Celgene Corporation | $354.36 | 2019-2025 | Reblozyl, Pomalyst |
| Sanofi-Aventis U.S. LLC | $299.92 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $297.53 | 2021-2025 | |
| Janssen Biotech, INC. | $285.43 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Seagen INC. | $281.24 | 2020-2023 | Adcetris, Tukysa |
| Astellas Pharma US INC | $276.78 | 2020-2025 | Xtandi, Xospata, Vyloy |
| Glaxosmithkline, LLC. | $240.97 | 2023-2025 | Ojjaara, Zejula, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $213.23 | 2020-2025 | Opdivo, Opdualag |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Klarnet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.